News Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 04:00:02 2024-05-03 pm EDT			5-day change	1st Jan Change
149.3 ^USD	-0.43%		+2.14%	-4.77%

May. 03	Johnson & Johnson Says Erleada Combination Therapy Achieves 100% BCR-Free Rate	MT
May. 03	J&J: to present advances in retinal diseases	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson Says Erleada Combination Therapy Achieves 100% BCR-Free Rate	May. 03	MT
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease	May. 03	AQ
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual 'Prepackaged' Reorganization	May. 03	AQ
J&J: to present advances in retinal diseases	May. 03	CF
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	May. 02
J&J: applies to the EMA for an extended MA for Tremfya	May. 02	CF
Johnson & Johnson : 2024 First-Quarter Press Release & Supplemental Schedules (April 16, 2024)	May. 02	PU
Johnson & Johnson : Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization Press Release	May. 02	PU
Sector Update: Health Care Stocks Rise Late Afternoon	May. 01	MT
Stocks rise after Fed rate decision, Powell press conference	May. 01	RE
Sector Update: Health Care Stocks Advance Wednesday Afternoon	May. 01	MT
Top Midday Stories: CVS Reports Q1 Earnings Miss, Lowers Outlook; ADP Q1 Earnings Top Estimates; J&J Proposes $6.5 Billion Settlement for Talc Lawsuits	May. 01	MT
Johnson & Johnson Seeks EU Approval for Ulcerative Colitis, Crohn’s Disease Drug	May. 01	MT
Nasdaq, S&P 500 fall as investors take cover before Fed decision	May. 01	RE
Johnson & Johnson Announces $6.48 Billion Plan for Unit to Resolve Ovarian Cancer Talc Claims	May. 01	MT
Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167	May. 01	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	May. 01	MT
Sector Update: Health Care	May. 01	MT
Transcript : Johnson & Johnson - Special Call	May. 01
J&J subsidiary proposes paying about $6.48B over 25 years to settle talc ovarian cancer lawsuits	May. 01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST